Abstract
Pulmonary arterial hypertension (PAH) is one of the leading causes of death in systemic sclerosis (SSc). Despite advances in treatment options for PAH, long-term prognosis remains poor for scleroderma-associated PAH (SSc-PAH). Although prompt diagnosis and treatment of PAH may have significant impact on survival rates, early detection of the syndrome continues to be challenging in SSc due to several factors ranging from limitations of the current screening tools and the complexities of the disease. In comparison with other PAH subgroups, SSc-PAH patients respond poorly to conventional forms of PAH therapy. Recent findings indicate that factors such as autoimmune and inflammatory responses, more severe vasculature remodeling, and intrinsic cardiac involvement may account for these differences.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 293-304 |
| Number of pages | 12 |
| Journal | Presse Medicale |
| Volume | 43 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 1 2014 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Update in systemic sclerosis-associated pulmonary arterial hypertension. / Gashouta, Mohamed A.; Humbert, Marc; Hassoun, Paul M.
In: Presse Medicale, Vol. 43, No. 10, 01.10.2014, p. 293-304.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Update in systemic sclerosis-associated pulmonary arterial hypertension
AU - Gashouta, Mohamed A.
AU - Humbert, Marc
AU - Hassoun, Paul M
PY - 2014/10/1
Y1 - 2014/10/1
N2 - Pulmonary arterial hypertension (PAH) is one of the leading causes of death in systemic sclerosis (SSc). Despite advances in treatment options for PAH, long-term prognosis remains poor for scleroderma-associated PAH (SSc-PAH). Although prompt diagnosis and treatment of PAH may have significant impact on survival rates, early detection of the syndrome continues to be challenging in SSc due to several factors ranging from limitations of the current screening tools and the complexities of the disease. In comparison with other PAH subgroups, SSc-PAH patients respond poorly to conventional forms of PAH therapy. Recent findings indicate that factors such as autoimmune and inflammatory responses, more severe vasculature remodeling, and intrinsic cardiac involvement may account for these differences.
AB - Pulmonary arterial hypertension (PAH) is one of the leading causes of death in systemic sclerosis (SSc). Despite advances in treatment options for PAH, long-term prognosis remains poor for scleroderma-associated PAH (SSc-PAH). Although prompt diagnosis and treatment of PAH may have significant impact on survival rates, early detection of the syndrome continues to be challenging in SSc due to several factors ranging from limitations of the current screening tools and the complexities of the disease. In comparison with other PAH subgroups, SSc-PAH patients respond poorly to conventional forms of PAH therapy. Recent findings indicate that factors such as autoimmune and inflammatory responses, more severe vasculature remodeling, and intrinsic cardiac involvement may account for these differences.
UR - http://www.scopus.com/inward/record.url?scp=84908401106&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84908401106&partnerID=8YFLogxK
U2 - 10.1016/j.lpm.2014.06.007
DO - 10.1016/j.lpm.2014.06.007
M3 - Article
C2 - 25179278
AN - SCOPUS:84908401106
VL - 43
SP - 293
EP - 304
JO - Presse Medicale
JF - Presse Medicale
SN - 0755-4982
IS - 10
ER -